Prevalence of Autoantibodies (ACPA) and Rheumatoid Factor among Rheumatoid Arthritis Patients in Sulaymaniyah
DOI:
https://doi.org/10.56056/amj.2024.269Keywords:
Anticitrullinated protein antibodies, Rheumatoid arthritis, Rheumatoid factor, Risk factorsAbstract
Background and objectives: Rheumatoid factor and anticitrullinated protein antibodies are the most characteristic autoantibodies for rheumatoid arthritis. Our aims were to evaluate the prevalence of Rheumatoid factor and anticitrullinated protein antibodies and their association with demographic and clinical characteristics of patients with RA.
Methods: This is a cross-sectional study which was conducted at Rheumatology and Rehabilitation Center/Sulaymaniyah from February 2022 to November 2022. The study included patients with rheumatoid arthritis from both sexes. Socio-demographic and clinical data were collected. Enzyme linked immunosorbent assay was used to estimate serum levels of rheumatoid factor and anticitrullinated protein antibodies antibody titer.
Results: The prevalence of rheumatoid factor was 72.61%. Each of high disease activity, mean DAS28 scores, rheumatoid nodules and deformities were significantly associated with rheumatoid factor positivity (P= 0.015, P= 0.025, P= 0.007 and P<0.001, respectively). The prevalence of anticitrullinated protein antibodies was 68.87%. High disease activity, rheumatoid nodules and deformities were significantly associated with anticitrullinated protein antibodies (P= 0.014, P<0.001 and P<0.001, respectively).
Conclusions: The prevalence of rheumatoid factor and anticitrullinated protein antibodies among patients with rheumatoid arthritis was within the global context. High disease activity and the presence of rheumatoid nodules are positively associated with rheumatoid factor-positivity. Number of tender joints and the presence of rheumatoid nodules were positively associated with anticitrullinated protein antibodies-positivity.
Downloads
References
Kurowska W, Kuca-Warnawin EH, Radzikowska A, Ma?li?ski W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent Eur J Immunol. 2017;42(4):390-8. DOI: 10.4103/tcmj.tcmj_116_18
De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004;63(12):1587-93. DOI: 10.1136/ard.2003.017574
.Scott DL, Smith C, Kingsley G. Joint damage and disability in rheumatoid arthritis: an updated systematic review. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S20-7.
Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K. et al. diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808. DOI: 10.7326/0003-4819-146-11-200706050-00008
Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35(6):727-34. DOI: 10.1155/2013/726598
Aletaha D, Alasti F, Smolen JS. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:229. DOI: 10.1186/s13075-015-0736-9
Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, et al. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol. 2014;41:2361–9. DOI: 10.3899/jrheum.140082
Seri A, Mohamed H, Adam ME, Elagib EM, Eltahirm NIA, Mansour SMA, et al. Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis among Sudanese patients and the relation between the serotype and joint involvement: a cohort study. Open Access Rheumatol. 2021; 13:325-332. DOI: 10.2147/OARRR.S339134
Sung W, Tsai W. Rethink about the role of rheumatoid factor and anti-citrullinated protein antibody in rheumatoid arthritis. Rheumatol Immunol Res. 2021; 2: 19-25. DOI.org/10.2478/rir-2021-003
Ridha A, Hussein S, AlJabban A, Gunay LM, Gorial FI, Al Ani NA. The clinical impact of seropositivity on treatment response in patients with rheumatoid arthritis treated with etanercept: a real-world Iraqi experience. Open Access Rheumatol. 2022;14;14:113-121. doi: 10.2147/OARRR.S368190.
Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013; 35(6):727-34. DOI: 10.1155/2013/726598.
Hannech E, Ben Tekaya A, Saidane O, Bouden S, Leila R, Tekaya R, et al. Comorbidities profiles in seropositive rheumatoid arthritis versus seronegative rheumatoid arthritis. Ann Rheum dis. 2022; 81(suppl. 1). DOI.org/10.1136/1nnrheumdis-2022-eular.336
Baka Z, Buzás E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther. 2009;11(4):238. DOI.org/10.1186/ar3751
Ouali S, Zemri K, Sellam F, Harir N, Beniassa Z, Herbi S, et al. Is there an association between anti-citrullinated peptide antibodies and the severity of rheumatoid arthritis parameters in Algerian patients? J Drug Deliv Therapeut. 2020;10(4):17–24). DOI: 10.1002/acr.23106
Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, et al. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol. 2014;41(12):2361–2369). DOI: 10.3899/jrheum.140082
Sarikaya Y, Sandal Uzun G, Ata EB, Arslan S, Ekici M, Durhan G, et al. Pulmonary rheumatoid nodules: does serologic status matter? Ann Rheum Dis. 2022; 81 (suppl. 1). doi.org/10.1136/annrheumdis-2022-eular.2526
Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann. Rheum. Dis. 2003, 62, 870–874. DOI: 10.1136/ard.62.9.870
Geraldino-Pardilla L, Giles JT, Sokolove J, Zartoshti A, Robinson WH, Budoff M, et al. Association of anti-citrullinated peptide antibodies with coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1276-1281. DOI: 10.1002/acr.23106
Sohn DH, Rhodes C, Onuma K, Zhao X, Sharpe O, Gazitt T, et al. Local joint inflammation and histone citrullination in a murine model of the transition from preclinical autoimmunity to inflammatory arthritis. Arthritis Rheumatol 2015; 67:2877–87. DOI.org/10.1002/art.39283
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011, 365, 2205–2219. DOI: 10.1056/NEJMra1004965.
Ursum J, Bos WH, van Dillen N, Dijkmans BA, van Schaardenburg D. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther. 2010;12(1):R8. DOI: 10.1186/ar2907
Murata K, Ito H, Hashimoto M, Murakami K, Watanabe R, Tanaka M, et al. Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort. Arthritis Res Ther 2020;22, 268. doi.org/10.1186/s13075-020-02366-x
Anquetil F, Clavel C, Offer G, Serre G, Sebbag M. IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies. J Immunol 2015; 194:3664–74DOI: 10.4049/jimmunol.1402334
Ge C, Tong D, Liang B, Lönnblom E, Schneider N, Hagert C, et al. Anti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage. JCI Insight 2017, 2. DOI: 10.1172/jci.insight.93688
Wu CY, Yang HY, Lai JH. Anti-citrullinated protein antibodies in patients with rheumatoid arthritis: biological effects and mechanisms of immunopathogenesis. Int J Mol Sci. 2020 Jun 4;21(11):4015. DOI: 10.3390/ijms21114015
De Rycke L, Peene I, Hoffman IEA, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis 2004;63:1587 – 93 DOI: 10.1136/ard.2003.017574
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zhwan Ebrahem Muhillddin, Raouf Rahim Merza
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
